ONE MAIN STREET, CAMBRIDGE, MA
Investor Presentation
Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Shareholder votes
Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases, Investor Presentation
Earnings Release
Annual Report to Security Holders
Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Phase 2b Trial Success for Zipalertinib in NSCLC Patients with EGFR Mutations
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload